Mark Weeks

Cooley advised Apollo Endosurgery, a medical device company, on its agreement to be acquired by Boston Scientific in an all-cash transaction with an enterprise value of approximately $615 million.

Cooley advised Tmunity Therapeutics, a clinical-stage biotechnology company, on its agreement to sell to Kite, a global biopharmaceutical company. Partners Mark Weeks, Ben Beerle and Marya Postner led the Cooley team.

Cooley advised Rani Therapeutics on its $73.3 million initial public offering of 6,666,667 shares of Class A common stock. Rani Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol RANI, is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics. Partners Josh Seidenfeld, Mark Weeks, John McKenna and Charlie Kim led the Cooley team.

Cooley advised Unchained Labs on its agreement to sell to The Carlyle Group, a publicly traded global investment firm, for $435 million. Partners Mark Weeks, Anne Lieberman and Al Browne led the Cooley team advising Unchained Labs, a life sciences tools company focused on solving problems for biologics and gene therapy researchers. 

Read more

Cooley advised NeuroPace on its $117.3 million initial public offering of 6,900,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. NeuroPace, whose securities now trade on the Nasdaq Global Market under the symbol NPCE, is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy. Partners Mark Weeks and Seth Gottlieb led the Cooley team.